APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-Oncology

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Selected research

Market Structure

Global Immuno-Oncology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025184 pages

Choose your research edition.

Industry ResearchImmuno-Oncology Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-Oncology Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Immuno-Oncology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-Oncology Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-Oncology Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.

Report Includes

Read the full market overview

This report provides an overview of the global Immuno-Oncology market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immuno-Oncology and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immuno-Oncology revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Immuno-Oncology market size, projected growth trends, production technologies, key applications, and end-use industries.

Immuno-Oncology Segment by Company

Bristol-Myers Squibb

Merck & Co., Inc.

Roche AG

AstraZeneca, Plc

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

Merck KGaA

Immuno-Oncology Segment by Type

Immune Checkpoint Inhibitors

Cytokine-Based Immunotherapy

Cancer Vaccines

CAR-T Cell Therapy

Others

Immuno-Oncology Segment by Application

Hospitals

Drugstores

Others

Immuno-Oncology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Immuno-Oncology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immuno-Oncology industry.

Chapter 3: Detailed analysis of Immuno-Oncology companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-Oncologyrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immuno-Oncology Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Immune Checkpoint Inhibitors Table 3. Key Players of Cytokine-Based Immunotherapy Table 4. Key Players of Cancer Vaccines Table 3. Key Players of CAR-T Cell Therapy Table 4. Key Players of Others Table 5. Global Immuno-Oncology Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospitals Table 7. Key Players of Drugstores Table 8. Key Players of Others Table 9. Global Immuno-Oncology Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Immuno-Oncology Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Immuno-Oncology Market Share by Region (2021-2026) Table 12. Global Immuno-Oncology Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Immuno-Oncology Market Share by Region (2027-2032) Table 14. Immuno-Oncology Industry Trends Table 15. Immuno-Oncology Industry Drivers Table 16. Immuno-Oncology Industry Opportunities and Challenges Table 17. Immuno-Oncology Industry Restraints Table 18. Global Immuno-Oncology Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Immuno-Oncology Revenue Market Share by Company (2021-2026) Table 20. Global Immuno-Oncology Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Immuno-Oncology Key Company Head Office and Area Served Table 22. Global Immuno-Oncology Company, Product Type & Application Table 23. Global Immuno-Oncology Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Immuno-Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Immuno-Oncology Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Immuno-Oncology Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Immuno-Oncology Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Immuno-Oncology Revenue Market Share by Type (2021-2026) Table 30. Global Immuno-Oncology Revenue Market Share by Type (2027-2032) Table 31. Global Immuno-Oncology Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Immuno-Oncology Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Immuno-Oncology Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Immuno-Oncology Revenue Market Share by Application (2021-2026) Table 35. Global Immuno-Oncology Revenue Market Share by Application (2027-2032) Table 36. Bristol-Myers Squibb Company Information Table 37. Bristol-Myers Squibb Business Overview Table 38. Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Bristol-Myers Squibb Immuno-Oncology Product Portfolio Table 40. Bristol-Myers Squibb Recent Development Table 41. Merck & Co., Inc. Company Information Table 42. Merck & Co., Inc. Business Overview Table 43. Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Merck & Co., Inc. Immuno-Oncology Product Portfolio Table 45. Merck & Co., Inc. Recent Development Table 46. Roche AG Company Information Table 47. Roche AG Business Overview Table 48. Roche AG Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Roche AG Immuno-Oncology Product Portfolio Table 50. Roche AG Recent Development Table 51. AstraZeneca, Plc Company Information Table 52. AstraZeneca, Plc Business Overview Table 53. AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. AstraZeneca, Plc Immuno-Oncology Product Portfolio Table 55. AstraZeneca, Plc Recent Development Table 56. Sanofi S.A. Company Information Table 57. Sanofi S.A. Business Overview Table 58. Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Sanofi S.A. Immuno-Oncology Product Portfolio Table 60. Sanofi S.A. Recent Development Table 61. Dendreon Pharmaceuticals Company Information Table 62. Dendreon Pharmaceuticals Business Overview Table 63. Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio Table 65. Dendreon Pharmaceuticals Recent Development Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Novartis Immuno-Oncology Product Portfolio Table 70. Novartis Recent Development Table 71. Gilead Sciences Inc. Company Information Table 72. Gilead Sciences Inc. Business Overview Table 73. Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Gilead Sciences Inc. Immuno-Oncology Product Portfolio Table 75. Gilead Sciences Inc. Recent Development Table 76. Merck KGaA Company Information Table 77. Merck KGaA Business Overview Table 78. Merck KGaA Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Merck KGaA Immuno-Oncology Product Portfolio Table 80. Merck KGaA Recent Development Table 81. North America Immuno-Oncology Market Size by Type (2021-2026) & (US$ Million) Table 82. North America Immuno-Oncology Market Size by Type (2027-2032) & (US$ Million) Table 83. North America Immuno-Oncology Market Size by Application (2021-2026) & (US$ Million) Table 84. North America Immuno-Oncology Market Size by Application (2027-2032) & (US$ Million) Table 85. North America Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. North America Immuno-Oncology Market Size by Country (2021-2026) Table 87. North America Immuno-Oncology Market Size by Country (2027-2032) Table 88. Europe Immuno-Oncology Market Size by Type (2021-2026) & (US$ Million) Table 89. Europe Immuno-Oncology Market Size by Type (2027-2032) & (US$ Million) Table 90. Europe Immuno-Oncology Market Size by Application (2021-2026) & (US$ Million) Table 91. Europe Immuno-Oncology Market Size by Application (2027-2032) & (US$ Million) Table 92. Europe Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Europe Immuno-Oncology Market Size by Country (2021-2026) Table 94. Europe Immuno-Oncology Market Size by Country (2027-2032) Table 95. China Immuno-Oncology Market Size by Type (2021-2026) & (US$ Million) Table 96. China Immuno-Oncology Market Size by Type (2027-2032) & (US$ Million) Table 97. China Immuno-Oncology Market Size by Application (2021-2026) & (US$ Million) Table 98. China Immuno-Oncology Market Size by Application (2027-2032) & (US$ Million) Table 99. Asia Immuno-Oncology Market Size by Type (2021-2026) & (US$ Million) Table 100. Asia Immuno-Oncology Market Size by Type (2027-2032) & (US$ Million) Table 101. Asia Immuno-Oncology Market Size by Application (2021-2026) & (US$ Million) Table 102. Asia Immuno-Oncology Market Size by Application (2027-2032) & (US$ Million) Table 103. Asia Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Asia Immuno-Oncology Market Size by Country (2021-2026) Table 105. Asia Immuno-Oncology Market Size by Country (2027-2032) Table 106. South America, Middle East & Africa Immuno-Oncology Market Size by Type (2021-2026) & (US$ Million) Table 107. South America, Middle East & Africa Immuno-Oncology Market Size by Type (2027-2032) & (US$ Million) Table 108. South America, Middle East & Africa Immuno-Oncology Market Size by Application (2021-2026) & (US$ Million) Table 109. South America, Middle East & Africa Immuno-Oncology Market Size by Application (2027-2032) & (US$ Million) Table 110. South America, Middle East & Africa Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. South America, Middle East & Africa Immuno-Oncology Market Size by Country (2021-2026) Table 112. South America, Middle East & Africa Immuno-Oncology Market Size by Country (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Immuno-Oncology Product Image Figure 2. Global Immuno-Oncology Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Immuno-Oncology Market Share by Type: 2025 VS 2032 Figure 4. Immune Checkpoint Inhibitors Image Figure 5. Cytokine-Based Immunotherapy Image Figure 6. Cancer Vaccines Image Figure 7. CAR-T Cell Therapy Image Figure 8. Others Image Figure 9. Global Immuno-Oncology Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Immuno-Oncology Market Share by Application: 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Drugstores Image Figure 13. Others Image Figure 14. Global Immuno-Oncology Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 16. Global Immuno-Oncology Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Immuno-Oncology Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Immuno-Oncology Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Immuno-Oncology Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Immuno-Oncology Revenue Market Share by Type (2021-2032) Figure 23. Global Immuno-Oncology Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Immuno-Oncology Revenue Market Share by Application (2021-2032) Figure 25. North America Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 26. North America Immuno-Oncology Market Share by Type (2021-2032) Figure 27. North America Immuno-Oncology Market Share by Application (2021-2032) Figure 28. North America Immuno-Oncology Market Share by Country (2021-2032) Figure 29. United States Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 30. Canada Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 32. Europe Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 33. Europe Immuno-Oncology Market Share by Type (2021-2032) Figure 34. Europe Immuno-Oncology Market Share by Application (2021-2032) Figure 35. Europe Immuno-Oncology Market Share by Country (2021-2032) Figure 36. Germany Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 37. France Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 39. Italy Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 40. Russia Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 42. China Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 43. China Immuno-Oncology Market Share by Type (2021-2032) Figure 44. China Immuno-Oncology Market Share by Application (2021-2032) Figure 45. Asia Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 46. Asia Immuno-Oncology Market Share by Type (2021-2032) Figure 47. Asia Immuno-Oncology Market Share by Application (2021-2032) Figure 48. Asia Immuno-Oncology Market Share by Country (2021-2032) Figure 49. Japan Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 53. India Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 54. Australia Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Immuno-Oncology Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Immuno-Oncology Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Immuno-Oncology Market Share by Country (2021-2032) Figure 59. Brazil Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 64. UAE Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 66. Chile Immuno-Oncology Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Checkpoint Inhibitors
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Roche AG
  • AstraZeneca, Plc
  • Sanofi S.A.
  • Dendreon Pharmaceuticals
  • Novartis
  • Gilead Sciences Inc.
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Immuno-Oncology Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Immune Checkpoint Inhibitors
  5. 1.2.3 Cytokine-Based Immunotherapy
  6. 1.2.4 Cancer Vaccines
  7. 1.2.5 CAR-T Cell Therapy
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Immuno-Oncology Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Drugstores
  13. 1.3.4 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Immuno-Oncology Growth Trends by Region
  16. 1.5.1 Global Immuno-Oncology Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Immuno-Oncology Market Size by Region (2021-2026)
  18. 1.5.3 Immuno-Oncology Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Immuno-Oncology Market Dynamics
  1. 2.1 Immuno-Oncology Industry Trends
  2. 2.2 Immuno-Oncology Industry Drivers
  3. 2.3 Immuno-Oncology Industry Opportunities and Challenges
  4. 2.4 Immuno-Oncology Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Immuno-Oncology Revenue by Company (2021-2026)
  2. 3.2 Global Immuno-Oncology Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Immuno-Oncology Key Company Head office and Area Served
  4. 3.4 Global Immuno-Oncology Company, Product Type & Application
  5. 3.5 Global Immuno-Oncology Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Immuno-Oncology Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Immuno-Oncology Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Immuno-Oncology Tier 1, Tier 2, and Tier 3
4 Immuno-Oncology Market by Type
  1. 4.1 Global Immuno-Oncology Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Immuno-Oncology Market Size by Type (2021-2032)
  3. 4.3 Global Immuno-Oncology Market Size Share by Type (2021-2032)
5 Immuno-Oncology Market by Application
  1. 5.1 Global Immuno-Oncology Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Immuno-Oncology Market Size by Application (2021-2032)
  3. 5.3 Global Immuno-Oncology Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Bristol-Myers Squibb
  2. 6.1.1 Bristol-Myers Squibb Company Information
  3. 6.1.2 Bristol-Myers Squibb Business Overview
  4. 6.1.3 Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Bristol-Myers Squibb Immuno-Oncology Product Portfolio
  6. 6.1.5 Bristol-Myers Squibb Recent Developments
  7. 6.2 Merck & Co., Inc.
  8. 6.2.1 Merck & Co., Inc. Company Information
  9. 6.2.2 Merck & Co., Inc. Business Overview
  10. 6.2.3 Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Merck & Co., Inc. Immuno-Oncology Product Portfolio
  12. 6.2.5 Merck & Co., Inc. Recent Developments
  13. 6.3 Roche AG
  14. 6.3.1 Roche AG Company Information
  15. 6.3.2 Roche AG Business Overview
  16. 6.3.3 Roche AG Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Roche AG Immuno-Oncology Product Portfolio
  18. 6.3.5 Roche AG Recent Developments
  19. 6.4 AstraZeneca, Plc
  20. 6.4.1 AstraZeneca, Plc Company Information
  21. 6.4.2 AstraZeneca, Plc Business Overview
  22. 6.4.3 AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 AstraZeneca, Plc Immuno-Oncology Product Portfolio
  24. 6.4.5 AstraZeneca, Plc Recent Developments
  25. 6.5 Sanofi S.A.
  26. 6.5.1 Sanofi S.A. Company Information
  27. 6.5.2 Sanofi S.A. Business Overview
  28. 6.5.3 Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Sanofi S.A. Immuno-Oncology Product Portfolio
  30. 6.5.5 Sanofi S.A. Recent Developments
  31. 6.6 Dendreon Pharmaceuticals
  32. 6.6.1 Dendreon Pharmaceuticals Company Information
  33. 6.6.2 Dendreon Pharmaceuticals Business Overview
  34. 6.6.3 Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio
  36. 6.6.5 Dendreon Pharmaceuticals Recent Developments
  37. 6.7 Novartis
  38. 6.7.1 Novartis Company Information
  39. 6.7.2 Novartis Business Overview
  40. 6.7.3 Novartis Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Novartis Immuno-Oncology Product Portfolio
  42. 6.7.5 Novartis Recent Developments
  43. 6.8 Gilead Sciences Inc.
  44. 6.8.1 Gilead Sciences Inc. Company Information
  45. 6.8.2 Gilead Sciences Inc. Business Overview
  46. 6.8.3 Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Gilead Sciences Inc. Immuno-Oncology Product Portfolio
  48. 6.8.5 Gilead Sciences Inc. Recent Developments
  49. 6.9 Merck KGaA
  50. 6.9.1 Merck KGaA Company Information
  51. 6.9.2 Merck KGaA Business Overview
  52. 6.9.3 Merck KGaA Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Merck KGaA Immuno-Oncology Product Portfolio
  54. 6.9.5 Merck KGaA Recent Developments
7 North America
  1. 7.1 North America Immuno-Oncology Market Size (2021-2032)
  2. 7.2 North America Immuno-Oncology Market Size by Type
  3. 7.2.1 North America Immuno-Oncology Market Size by Type (2021-2026)
  4. 7.2.2 North America Immuno-Oncology Market Size by Type (2027-2032)
  5. 7.2.3 North America Immuno-Oncology Market Share by Type (2021-2032)
  6. 7.3 North America Immuno-Oncology Market Size by Application
  7. 7.3.1 North America Immuno-Oncology Market Size by Application (2021-2026)
  8. 7.3.2 North America Immuno-Oncology Market Size by Application (2027-2032)
  9. 7.3.3 North America Immuno-Oncology Market Share by Application (2021-2032)
  10. 7.4 North America Immuno-Oncology Market Size by Country
  11. 7.4.1 North America Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Immuno-Oncology Market Size by Country (2021-2026)
  13. 7.4.3 North America Immuno-Oncology Market Size by Country (2027-2032)
  14. 7.4.4 North America Immuno-Oncology Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Immuno-Oncology Market Size (2021-2032)
  2. 8.2 Europe Immuno-Oncology Market Size by Type
  3. 8.2.1 Europe Immuno-Oncology Market Size by Type (2021-2026)
  4. 8.2.2 Europe Immuno-Oncology Market Size by Type (2027-2032)
  5. 8.2.3 Europe Immuno-Oncology Market Share by Type (2021-2032)
  6. 8.3 Europe Immuno-Oncology Market Size by Application
  7. 8.3.1 Europe Immuno-Oncology Market Size by Application (2021-2026)
  8. 8.3.2 Europe Immuno-Oncology Market Size by Application (2027-2032)
  9. 8.3.3 Europe Immuno-Oncology Market Share by Application (2021-2032)
  10. 8.4 Europe Immuno-Oncology Market Size by Country
  11. 8.4.1 Europe Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Immuno-Oncology Market Size by Country (2021-2026)
  13. 8.4.3 Europe Immuno-Oncology Market Size by Country (2027-2032)
  14. 8.4.4 Europe Immuno-Oncology Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Immuno-Oncology Market Size (2021-2032)
  2. 9.2 China Immuno-Oncology Market Size by Type
  3. 9.2.1 China Immuno-Oncology Market Size by Type (2021-2026)
  4. 9.2.2 China Immuno-Oncology Market Size by Type (2027-2032)
  5. 9.2.3 China Immuno-Oncology Market Share by Type (2021-2032)
  6. 9.3 China Immuno-Oncology Market Size by Application
  7. 9.3.1 China Immuno-Oncology Market Size by Application (2021-2026)
  8. 9.3.2 China Immuno-Oncology Market Size by Application (2027-2032)
  9. 9.3.3 China Immuno-Oncology Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Immuno-Oncology Market Size (2021-2032)
  2. 10.2 Asia Immuno-Oncology Market Size by Type
  3. 10.2.1 Asia Immuno-Oncology Market Size by Type (2021-2026)
  4. 10.2.2 Asia Immuno-Oncology Market Size by Type (2027-2032)
  5. 10.2.3 Asia Immuno-Oncology Market Share by Type (2021-2032)
  6. 10.3 Asia Immuno-Oncology Market Size by Application
  7. 10.3.1 Asia Immuno-Oncology Market Size by Application (2021-2026)
  8. 10.3.2 Asia Immuno-Oncology Market Size by Application (2027-2032)
  9. 10.3.3 Asia Immuno-Oncology Market Share by Application (2021-2032)
  10. 10.4 Asia Immuno-Oncology Market Size by Country
  11. 10.4.1 Asia Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Immuno-Oncology Market Size by Country (2021-2026)
  13. 10.4.3 Asia Immuno-Oncology Market Size by Country (2027-2032)
  14. 10.4.4 Asia Immuno-Oncology Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Immuno-Oncology Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Immuno-Oncology Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Immuno-Oncology Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Immuno-Oncology Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Immuno-Oncology Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Immuno-Oncology Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Immuno-Oncology Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Immuno-Oncology Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Immuno-Oncology Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Immuno-Oncology Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Immuno-Oncology Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Immuno-Oncology Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Immuno-Oncology Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Immuno-Oncology Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst